Defining at-risk populations for Parkinson's disease: Lessons from ongoing studies

被引:101
作者
Berg, Daniela [1 ,2 ]
Marek, Ken [3 ]
Ross, George W. [4 ,5 ]
Poewe, Werner [6 ]
机构
[1] Univ Tubingen, Dept Neurodegenerat, Hertie Inst Clin Brain Res, D-72076 Tubingen, Germany
[2] Univ Tubingen, German Ctr Neurodegenerat Dis, D-72076 Tubingen, Germany
[3] Inst Neurodegenerat Disorders, New Haven, CT USA
[4] Kuakini Med Ctr, Honolulu, HI USA
[5] VA Pacific Isl Hlth Care Syst, Honolulu, HI USA
[6] Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria
关键词
preclinical Parkinson's disease; at-risk populations; population-based cohorts; enriched risk cohorts; SLEEP BEHAVIOR DISORDER; DOPAMINE TRANSPORTERS; LEWY BODY; OLFACTORY DYSFUNCTION; IDENTIFICATION TEST; IMPAIRED OLFACTION; SUBSTANTIA-NIGRA; DIAGNOSIS; SPECT; ASSOCIATION;
D O I
10.1002/mds.24985
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
It is currently widely acknowledged that the natural history of PD includes a preclinical phase, and there are increasing efforts to identify markers that would allow the identification of individuals at risk for PD. Here, we discuss the issues related to defining at-risk populations for PD and review findings of current population-based cohorts that have reported potential biomarkers for PD, such as the Honolulu-Asia Aging Study (HAAS) and the PRIPS (Prospective Validation of Risk factors for the development of Parkinson Syndromes) study. We also discuss enriched risk cohorts designed to evaluate specificity and predictive value of markers exemplified by the PARS (Parkinson Associated Risk Study) and the TREND (Tubinger evaluation of Risk factors for the Early detection of NeuroDegeneration) study. Although there is still a long way to go, studies designed according to these concepts might eventually provide sufficient data to form the basis for future screening programs for PD risk to be applied at a population level. (C) 2012 Movement Disorder Society
引用
收藏
页码:656 / 665
页数:10
相关论文
共 60 条
  • [11] What more can we learn from studying the REM sleep behaviour disorder - Parkinson's disease association?
    Boeve, Bradley F.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2008, 79 (10) : 1087 - 1087
  • [12] Booij J, 1998, J NUCL MED, V39, P1879
  • [13] Braak H, 2009, ADV ANAT EMBRYOL CEL, V201, P1
  • [14] Staging of brain pathology related to sporadic Parkinson's disease
    Braak, H
    Del Tredici, K
    Rüb, U
    de Vos, RAI
    Steur, ENHJ
    Braak, E
    [J]. NEUROBIOLOGY OF AGING, 2003, 24 (02) : 197 - 211
  • [15] Impact of dopamine transporter SPECT using 123I-ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes
    Catafau, AM
    Tolosa, E
    [J]. MOVEMENT DISORDERS, 2004, 19 (10) : 1175 - 1182
  • [16] Looking backward to move forward: Early detection of neurodegenerative disorders
    Dekosky, ST
    Marek, K
    [J]. SCIENCE, 2003, 302 (5646) : 830 - 834
  • [17] Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease
    Dickson, Dennis W.
    Fujishiro, Hiroshige
    DelleDonne, Anthony
    Menke, Joshua
    Ahmed, Zeshan
    Klos, Kevin J.
    Josephs, Keith A.
    Frigerio, Roberta
    Burnett, Melinda
    Parisi, Joseph E.
    Ahlskog, J. Eric
    [J]. ACTA NEUROPATHOLOGICA, 2008, 115 (04) : 437 - 444
  • [18] Development of the 12-item cross-cultural smell identification test (CC-SIT)
    Doty, RL
    Marcus, A
    Lee, WW
    [J]. LARYNGOSCOPE, 1996, 106 (03) : 353 - 356
  • [19] AGING AND PARKINSONS-DISEASE - SUBSTANTIA-NIGRA REGIONAL SELECTIVITY
    FEARNLEY, JM
    LEES, AJ
    [J]. BRAIN, 1991, 114 : 2283 - 2301
  • [20] Fischman AJ, 1998, SYNAPSE, V29, P128, DOI 10.1002/(SICI)1098-2396(199806)29:2<128::AID-SYN4>3.0.CO